MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-26-2026
Zai Lab Limited Operating Income 2011-2026 | ZLAB
Operating profit (also called operating income or profit from core activities) is a financial metric that reflects a company's profit from its main operational activities before interest expenses and taxes are taken into account.
FormulaOperating profit = Revenue – Operating expensesFeatures of the metric
- Evaluates business efficiency
Shows how well the company controls its production and administrative costs. - Independent of financial structure
Excludes the impact of debt burden (interest) and taxes, allowing objective comparison of companies. - Main source for growth
High operating profit provides resources for investments, business expansion, and increased competitiveness.
If a company shows strong operating profit, it signals to investors that the core business is operating efficiently, even if net profit is temporarily reduced due to debt or tax burden.
Annual Operating Income Zai Lab Limited
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -229 M | -282 M | -367 M | -404 M | -700 M | -302 M | -203 M | -142 M | -51.4 M | -38.5 M | -16.3 M | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -16.3 M | -700 M | -249 M |
Quarterly Operating Income Zai Lab Limited
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -48.8 M | -54.9 M | -56.3 M | - | -67.9 M | -76.1 M | -70.3 M | - | -83.6 M | -89.5 M | -69.5 M | - | -129 M | -98.7 M | -79.8 M | -219 M | -83.2 M | -171 M | -227 M | -95.3 M | -76.3 M | -84 M | -46.3 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -46.3 M | -227 M | -96.3 M |
Operating Income of other stocks in the Biotechnology industry
| Issuer | Operating Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
-508 M | - | 2.43 % | $ 254 M |  Germany |
 |
AbCellera Biologics
ABCL
|
-217 M | $ 3.44 | -4.32 % | $ 1.03 B |  Canada |
 |
Acorda Therapeutics
ACOR
|
-265 M | - | -24.86 % | $ 820 K |  USA |
 |
Acer Therapeutics
ACER
|
-24.6 M | - | 2.71 % | $ 14 M | USA |
 |
Biophytis SA
BPTS
|
-26.8 M | - | -13.47 % | $ 169 M |  France |
 |
ADMA Biologics
ADMA
|
191 M | $ 15.36 | -2.17 % | $ 3.66 B | USA |
 |
Cellectis S.A.
CLLS
|
-131 M | $ 3.53 | -3.54 % | $ 116 M | France |
 |
AgeX Therapeutics
AGE
|
-9.89 M | - | -10.17 % | $ 12.2 K | USA |
 |
Apellis Pharmaceuticals
APLS
|
55.4 M | $ 20.28 | 0.65 % | $ 2.56 B | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-210 M | - | - | $ 1.01 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
-17.7 M | - | - | $ 26.5 M | USA |
 |
Akero Therapeutics
AKRO
|
-285 M | - | - | $ 3.67 B | USA |
 |
Midatech Pharma plc
MTP
|
-7 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Akouos
AKUS
|
-86.8 M | - | 0.23 % | $ 488 M | USA |
 |
Alpine Immune Sciences
ALPN
|
-58.1 M | - | - | $ 2.17 B | USA |
 |
Nymox Pharmaceutical Corporation
NYMX
|
-12.5 M | - | -19.68 % | $ 18.4 M | Canada |
 |
AlloVir
ALVR
|
-65.4 M | - | 4.14 % | $ 49.1 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
-241 M | $ 1.51 | 1.35 % | $ 385 M | Britain |
 |
China SXT Pharmaceuticals
SXTC
|
-2.68 M | $ 2.01 | -1.36 % | $ 2.86 M |  China |
 |
Galmed Pharmaceuticals Ltd.
GLMD
|
-30.2 M | $ 0.67 | 7.08 % | $ 624 K |  Israel |
 |
Adverum Biotechnologies
ADVM
|
-139 M | - | - | $ 86.2 M | USA |
 |
Ampio Pharmaceuticals
AMPE
|
-33.3 M | - | -11.43 % | $ 502 K | USA |
 |
Anika Therapeutics
ANIK
|
-87.6 M | $ 14.05 | -1.44 % | $ 206 M | USA |
 |
ANI Pharmaceuticals
ANIP
|
584 K | $ 74.36 | -1.64 % | $ 1.44 B | USA |
 |
Applied Therapeutics
APLT
|
-64.5 M | - | - | $ 8.42 M | USA |
 |
Aravive
ARAV
|
-70.8 M | - | -13.39 % | $ 1.45 M | USA |
 |
ARCA biopharma
ABIO
|
-88.1 M | - | 1052.0 % | $ 415 M | USA |
 |
Athersys
ATHX
|
-87.1 M | - | 3.77 % | $ 22.4 M | USA |
 |
AVEO Pharmaceuticals
AVEO
|
-49.6 M | - | - | $ 521 M | USA |
 |
Axsome Therapeutics
AXSM
|
-167 M | $ 162.43 | 0.6 % | $ 8.08 B | USA |
 |
BioCryst Pharmaceuticals
BCRX
|
-2.54 M | $ 8.49 | -0.18 % | $ 1.75 B | USA |
 |
BridgeBio Pharma
BBIO
|
-523 M | $ 65.66 | -0.78 % | $ 12.6 B | USA |
 |
Acasti Pharma
ACST
|
-16.7 M | - | 4.01 % | $ 150 M | Canada |
 |
Brainstorm Cell Therapeutics
BCLI
|
-11.7 M | - | -2.5 % | $ 5.88 M | USA |
 |
BioDelivery Sciences International
BDSI
|
37.1 M | - | -4.8 % | $ 255 M | USA |
 |
BeiGene, Ltd.
BGNE
|
447 M | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Bellerophon Therapeutics
BLPH
|
-22.4 M | - | -74.18 % | $ 955 K | USA |
 |
Bellicum Pharmaceuticals
BLCM
|
-27 M | - | -9.72 % | $ 5.89 M | USA |
 |
Berkeley Lights
BLI
|
-98.1 M | - | -7.31 % | $ 87 M | USA |
 |
CureVac N.V.
CVAC
|
-412 M | - | - | $ 867 M | Germany |
 |
Aeterna Zentaris
AEZS
|
-8.67 M | - | 5.93 % | $ 314 M | Canada |
 |
BioLineRx Ltd.
BLRX
|
-24.8 M | $ 2.69 | -0.74 % | $ 908 M | Israel |
 |
BioMarin Pharmaceutical
BMRN
|
409 M | $ 61.3 | 1.21 % | $ 11.8 B | USA |
 |
Burford Capital Limited
BUR
|
242 M | $ 7.79 | -5.75 % | $ 1.28 B | Britain |
 |
CymaBay Therapeutics
CBAY
|
-102 M | - | - | $ 3.45 B | USA |